Studies of human C5a as a mediator of inflammation in normal human skin

K. B. Yancey, C. H. Hammer, L. Harvath, L. Renfer, M. M. Frank, T. J. Lawley

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

C5a is an 11,000-D fragment of the fifth component of complement (C5) with potent anaphylatoxic and leukocyte chemotactic activities. C5a is believed to play an important role in the pathophysiology of certain skin disorders and systemic diseases with cutaneous manifestations. However, there is very little known about the in vivo reactivity of C5a in man. In this study we examined the effects of intradermal injections of human C5a in 17 normal volunteers. C5a was prepared by interacting highly purified human C5 with zymosan bound alternative pathway C5 convertase under conditions resulting in consumption of ~90% of the C5 substrate. C5a produced in this manner was chemotactic for human neutrophils and monocytes (0.5 x 10-7 to 10-9 M) and caused neutrophil aggregation and myeloperoxidase release (concentrations ≥ 10-10 M) in vitro. In vivo, C5a produced immediate wheal and flare reactions in all volunteers, and was active in doses as low as 1 ng (10-13 mol). Intradermal testing with 20 ng of C5a in eight volunteers produced a maximal mean wheal of 11.75 mm (± 0.80 mm SEM) 20 min after anaphylatoxin injection, and a maximal mean erythema of 62.50 mm (± 3.27 mm SEM) 10 min after C5a administration. Reactions at C5a test sites were dose-related, associated with marked pruritus in some subjects, resolved without lesion formation, and were not associated with late phase reactions. In vivo testing revealed that human C5a was a more potent mediator of wheal and flare reactions than histamine, 48/80, human C3a, or morphine sulfate. Skin biopsies from eight volunteers 20 min after intradermal injection of 20 ng of C5a revealed a neutrophil-predominant perivascular infiltrate, endothelial cell edema, and sites of leukocytoclasis. Mast cell degranulation was observed on both light and electron microscopy of biopsies from C5a test sites. Although erythema at C5a injection sites was reduced by pretreating volunteers with hydroxyzine, whealing reactions and cellular infiltrates in biopsies were unaffected by this H1-antihistamine. Moderate doses of systemic corticosteroids did not alter clinical or histologic reactions at C5a injections sites in two volunteers. This study, using doses within the potential physiologic range of the anaphylatoxin, provides a comprehensive assessment of the effect of human C5a on normal human skin.

Original languageEnglish (US)
Pages (from-to)486-495
Number of pages10
JournalJournal of Clinical Investigation
Volume75
Issue number2
StatePublished - 1985

Fingerprint

Inflammation Mediators
Skin
Volunteers
Anaphylatoxins
Intradermal Injections
Neutrophils
Erythema
Alternative Pathway Complement C5 Convertase
Biopsy
Injections
Complement C5
Hydroxyzine
Skin Manifestations
Cell Degranulation
Zymosan
Histamine Antagonists
Pruritus
Mast Cells
Morphine
Histamine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yancey, K. B., Hammer, C. H., Harvath, L., Renfer, L., Frank, M. M., & Lawley, T. J. (1985). Studies of human C5a as a mediator of inflammation in normal human skin. Journal of Clinical Investigation, 75(2), 486-495.

Studies of human C5a as a mediator of inflammation in normal human skin. / Yancey, K. B.; Hammer, C. H.; Harvath, L.; Renfer, L.; Frank, M. M.; Lawley, T. J.

In: Journal of Clinical Investigation, Vol. 75, No. 2, 1985, p. 486-495.

Research output: Contribution to journalArticle

Yancey, KB, Hammer, CH, Harvath, L, Renfer, L, Frank, MM & Lawley, TJ 1985, 'Studies of human C5a as a mediator of inflammation in normal human skin', Journal of Clinical Investigation, vol. 75, no. 2, pp. 486-495.
Yancey KB, Hammer CH, Harvath L, Renfer L, Frank MM, Lawley TJ. Studies of human C5a as a mediator of inflammation in normal human skin. Journal of Clinical Investigation. 1985;75(2):486-495.
Yancey, K. B. ; Hammer, C. H. ; Harvath, L. ; Renfer, L. ; Frank, M. M. ; Lawley, T. J. / Studies of human C5a as a mediator of inflammation in normal human skin. In: Journal of Clinical Investigation. 1985 ; Vol. 75, No. 2. pp. 486-495.
@article{906d560b29234059984ac0dead78c134,
title = "Studies of human C5a as a mediator of inflammation in normal human skin",
abstract = "C5a is an 11,000-D fragment of the fifth component of complement (C5) with potent anaphylatoxic and leukocyte chemotactic activities. C5a is believed to play an important role in the pathophysiology of certain skin disorders and systemic diseases with cutaneous manifestations. However, there is very little known about the in vivo reactivity of C5a in man. In this study we examined the effects of intradermal injections of human C5a in 17 normal volunteers. C5a was prepared by interacting highly purified human C5 with zymosan bound alternative pathway C5 convertase under conditions resulting in consumption of ~90{\%} of the C5 substrate. C5a produced in this manner was chemotactic for human neutrophils and monocytes (0.5 x 10-7 to 10-9 M) and caused neutrophil aggregation and myeloperoxidase release (concentrations ≥ 10-10 M) in vitro. In vivo, C5a produced immediate wheal and flare reactions in all volunteers, and was active in doses as low as 1 ng (10-13 mol). Intradermal testing with 20 ng of C5a in eight volunteers produced a maximal mean wheal of 11.75 mm (± 0.80 mm SEM) 20 min after anaphylatoxin injection, and a maximal mean erythema of 62.50 mm (± 3.27 mm SEM) 10 min after C5a administration. Reactions at C5a test sites were dose-related, associated with marked pruritus in some subjects, resolved without lesion formation, and were not associated with late phase reactions. In vivo testing revealed that human C5a was a more potent mediator of wheal and flare reactions than histamine, 48/80, human C3a, or morphine sulfate. Skin biopsies from eight volunteers 20 min after intradermal injection of 20 ng of C5a revealed a neutrophil-predominant perivascular infiltrate, endothelial cell edema, and sites of leukocytoclasis. Mast cell degranulation was observed on both light and electron microscopy of biopsies from C5a test sites. Although erythema at C5a injection sites was reduced by pretreating volunteers with hydroxyzine, whealing reactions and cellular infiltrates in biopsies were unaffected by this H1-antihistamine. Moderate doses of systemic corticosteroids did not alter clinical or histologic reactions at C5a injections sites in two volunteers. This study, using doses within the potential physiologic range of the anaphylatoxin, provides a comprehensive assessment of the effect of human C5a on normal human skin.",
author = "Yancey, {K. B.} and Hammer, {C. H.} and L. Harvath and L. Renfer and Frank, {M. M.} and Lawley, {T. J.}",
year = "1985",
language = "English (US)",
volume = "75",
pages = "486--495",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Studies of human C5a as a mediator of inflammation in normal human skin

AU - Yancey, K. B.

AU - Hammer, C. H.

AU - Harvath, L.

AU - Renfer, L.

AU - Frank, M. M.

AU - Lawley, T. J.

PY - 1985

Y1 - 1985

N2 - C5a is an 11,000-D fragment of the fifth component of complement (C5) with potent anaphylatoxic and leukocyte chemotactic activities. C5a is believed to play an important role in the pathophysiology of certain skin disorders and systemic diseases with cutaneous manifestations. However, there is very little known about the in vivo reactivity of C5a in man. In this study we examined the effects of intradermal injections of human C5a in 17 normal volunteers. C5a was prepared by interacting highly purified human C5 with zymosan bound alternative pathway C5 convertase under conditions resulting in consumption of ~90% of the C5 substrate. C5a produced in this manner was chemotactic for human neutrophils and monocytes (0.5 x 10-7 to 10-9 M) and caused neutrophil aggregation and myeloperoxidase release (concentrations ≥ 10-10 M) in vitro. In vivo, C5a produced immediate wheal and flare reactions in all volunteers, and was active in doses as low as 1 ng (10-13 mol). Intradermal testing with 20 ng of C5a in eight volunteers produced a maximal mean wheal of 11.75 mm (± 0.80 mm SEM) 20 min after anaphylatoxin injection, and a maximal mean erythema of 62.50 mm (± 3.27 mm SEM) 10 min after C5a administration. Reactions at C5a test sites were dose-related, associated with marked pruritus in some subjects, resolved without lesion formation, and were not associated with late phase reactions. In vivo testing revealed that human C5a was a more potent mediator of wheal and flare reactions than histamine, 48/80, human C3a, or morphine sulfate. Skin biopsies from eight volunteers 20 min after intradermal injection of 20 ng of C5a revealed a neutrophil-predominant perivascular infiltrate, endothelial cell edema, and sites of leukocytoclasis. Mast cell degranulation was observed on both light and electron microscopy of biopsies from C5a test sites. Although erythema at C5a injection sites was reduced by pretreating volunteers with hydroxyzine, whealing reactions and cellular infiltrates in biopsies were unaffected by this H1-antihistamine. Moderate doses of systemic corticosteroids did not alter clinical or histologic reactions at C5a injections sites in two volunteers. This study, using doses within the potential physiologic range of the anaphylatoxin, provides a comprehensive assessment of the effect of human C5a on normal human skin.

AB - C5a is an 11,000-D fragment of the fifth component of complement (C5) with potent anaphylatoxic and leukocyte chemotactic activities. C5a is believed to play an important role in the pathophysiology of certain skin disorders and systemic diseases with cutaneous manifestations. However, there is very little known about the in vivo reactivity of C5a in man. In this study we examined the effects of intradermal injections of human C5a in 17 normal volunteers. C5a was prepared by interacting highly purified human C5 with zymosan bound alternative pathway C5 convertase under conditions resulting in consumption of ~90% of the C5 substrate. C5a produced in this manner was chemotactic for human neutrophils and monocytes (0.5 x 10-7 to 10-9 M) and caused neutrophil aggregation and myeloperoxidase release (concentrations ≥ 10-10 M) in vitro. In vivo, C5a produced immediate wheal and flare reactions in all volunteers, and was active in doses as low as 1 ng (10-13 mol). Intradermal testing with 20 ng of C5a in eight volunteers produced a maximal mean wheal of 11.75 mm (± 0.80 mm SEM) 20 min after anaphylatoxin injection, and a maximal mean erythema of 62.50 mm (± 3.27 mm SEM) 10 min after C5a administration. Reactions at C5a test sites were dose-related, associated with marked pruritus in some subjects, resolved without lesion formation, and were not associated with late phase reactions. In vivo testing revealed that human C5a was a more potent mediator of wheal and flare reactions than histamine, 48/80, human C3a, or morphine sulfate. Skin biopsies from eight volunteers 20 min after intradermal injection of 20 ng of C5a revealed a neutrophil-predominant perivascular infiltrate, endothelial cell edema, and sites of leukocytoclasis. Mast cell degranulation was observed on both light and electron microscopy of biopsies from C5a test sites. Although erythema at C5a injection sites was reduced by pretreating volunteers with hydroxyzine, whealing reactions and cellular infiltrates in biopsies were unaffected by this H1-antihistamine. Moderate doses of systemic corticosteroids did not alter clinical or histologic reactions at C5a injections sites in two volunteers. This study, using doses within the potential physiologic range of the anaphylatoxin, provides a comprehensive assessment of the effect of human C5a on normal human skin.

UR - http://www.scopus.com/inward/record.url?scp=0021969794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021969794&partnerID=8YFLogxK

M3 - Article

C2 - 2982914

AN - SCOPUS:0021969794

VL - 75

SP - 486

EP - 495

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -